Diverging EPO appeal decisions regarding the use of videoconferencing

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Diverging EPO appeal decisions regarding the use of videoconferencing

Sponsored by

inspicos-400px recrop.jpg
video-conference-1163880_1920.jpg

Jakob Pade Frederiksen of Inspicos says that clarification from the EPO Enlarged Board of Appeal may be necessary after a series of rulings concerning the format of oral proceedings in appeals

During the COVID pandemic, the EPO resorted to videoconferencing (ViCo) for holding oral proceedings in inter partes opposition cases, as well as in appeals. While the departments of first instance at the EPO have implemented the ViCo format as the default in first-instance oppositions, the legality – and, more widely, the applicability – of ViCO in appeals has been much debated.

EPO case law

In a decision of the EPO Enlarged Board of Appeal (EBA) handed down on October 28 2021, G 1/21, the EBA held that during a general emergency impairing the parties’ ability to attend in-person oral proceedings at the EPO premises, the conducting of oral proceedings before the boards of appeal by way of ViCo was not at odds with applicable law. The EBA, however, also expressed the view that in-person oral proceedings were the optimum format and should be the default option.

Subsequently, a technical board of appeal of the EPO decided, in decision T 1158/20 of November 22 2022, that holding oral proceedings by videoconference could often be considered an equivalent alternative to in-person oral proceedings in view of the experience that had been gained. Consistently, the same board of appeal decided on November 23 2022 in another case, T 758/20, that G 1/21 could not be read as restricting the possibility of summoning for oral proceedings by videoconference contrary to the will of one of the parties, only in the case of a general emergency.

However, another technical board of appeal held in a more recent decision, T 2432/19 of April 25 2023, that it followed from G 1/21 that in-person oral proceedings could only be denied under very limited conditions, even in a situation of general emergency such as a pandemic. Furthermore, due to the fact that videoconferences, at least with current technology, could only provide a suboptimal form of communication, parties had a right to the optimum format for oral proceedings – i.e., in-person oral proceedings – that could only be denied under very limited conditions.

An uncertain outlook?

It can only be speculated if the above decisions reflect diverging trends within the boards of appeal that will eventually necessitate a further case before the EBA to bring clarification.

more from across site and SHARED ros bottom lb

More from across our site

News of Avanci hiring a senior vice president and the EPO teaming up with a French AI startup were also among the top talking points
Explosm, the independent Texas studio behind the hit webcomic Cyanide & Happiness, partnered with Temu’s IP protection team to combat counterfeiters infringing on its brand
The latest in a dispute over juicing machines, and a shakeup in judicial compositions were also among the top developments
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Attain IP, developed by two UK patent lawyers, will meet ‘forensic’ needs of patent attorneys by showing a verifiable reasoning chain, according to its co-founders
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Gift this article